Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219637 | 0.95 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| SCHEMBL28814747 | 0.95 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| SCHEMBL840614 | 0.93 | METAP1 (0.45) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| SCHEMBL13274393 | 0.93 | METAP1 (0.45) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| SCHEMBL463976 | 0.93 | METAP1 (0.45) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| Hydrochloric Acid SCHEMBL27922161 | 0.92 | METAP1 (0.44) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| Hydrochloric Acid SCHEMBL27922164 | 0.92 | METAP1 (0.44) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| Formic Acid SCHEMBL27923729 | 0.87 | METAP1 (0.41) | SMN1; SMN2RAB9AGAANPC1MAPT | |
| SCHEMBL904231 | 0.83 | METAP1 (0.58) | SMN1; SMN2RAB9AGAAMAPTEPHX1 | |
| SCHEMBL15623642 | 0.83 | METAP1 (0.58) | SMN1; SMN2RAB9AGAAMAPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | SMN1; SMN2 4224/4885RAB9A 1782/4885GAA 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.